At the doses and schedule studied in this trial, sunitinib induced tumor vasculature normalization and inhibited lymphangiogenesis more prominently than bevacizumab, while bevacizumab demonstrated more significant effects on tumor VEGFR2 than sunitinib suggesting greater anti-angiogenic activity. Here, KDR is linked to neoplasm.